Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
HMS LINCS Database Resource Report Resource Website 10+ mentions |
HMS LINCS Database (RRID:SCR_006454) | LINCS, HMS-LINCS, HMS LINCS | data or information resource, data repository, database, service resource, storage service resource | Database that contains all publicly available HMS LINCS datasets and information for each dataset about experimental reagents and experimental and data analysis protocols. Experimental reagents include small molecule perturbagens, cells, antibodies, and proteins. | tumor, cancer, database, molecular signature, perturbing agent |
is used by: LINCS Information Framework is recommended by: National Library of Medicine is related to: Broad Institute is related to: OME-TIFF Format is related to: HMS LINCS Center has parent organization: Harvard Medical School; Massachusetts; USA is parent organization of: LINCS Connectivity Map |
Cancer, Diseased joint, Autoimmune disease | NHGRI U54 HG006097; NIH Common Fund |
Available to the research community | nlx_156062, r3d100011833 | http://lincs.hms.harvard.edu/, https://doi.org/10.17616/R3ZK9R | SCR_006454 | SciCrunch Registry | NIH LINCS Program, NIH LINCS, Harvard Medical School LINCS Database, LINCS Program, Library of Integrated Network-based Cellular Signatures | 2026-10-31 12:14:23 | 15 | ||||
|
Congressionally Directed Medical Research Program Resource Report Resource Website 50+ mentions |
Congressionally Directed Medical Research Program (RRID:SCR_006456) | CDMRP | nonprofit organization | Fund the best research to eradicate diseases and support the warfighter to benefit the American Public. They promote innovative research, recognizing untapped opportunities, creating partnerships, and guarding the public trust. Research Program topics include: * Amyotrophic Lateral Sclerosis * Autism * Bone Marrow Failure * Breast Cancer * Defense Medical Research and Development Program * Duchenne Muscular Dystrophy * Gulf War Illness * Lung Cancer * Multiple Sclerosis * Neurofibromatosis * Ovarian Cancer * Peer Reviewed Cancer * Peer Reviewed Medical * Peer Reviewed Orthopaedic * Prostate Cancer * Psychological Health / Traumatic Brain Injury * Spinal Cord Injury * Tuberous Sclerosis Complex | grant, funding, one mind tbi, one mind ptsd, medical, medical research, psychological health, orthopedic, peer review, biomedical |
is related to: NIDDK Information Network (dkNET) has parent organization: U.S. Department of Defense |
Amyotrophic Lateral Sclerosis, Autism, Bone marrow failure, Breast cancer, Duchenne muscular dystrophy, Gulf War Illness, Lung cancer, Multiple Sclerosis, Neurofibromatosis, Ovarian cancer, Cancer, Prostate cancer, Traumatic brain injury, Spinal cord injury, Tuberous sclerosis complex | United States Department of Defense | nif-0000-00443, grid.496791.4, Crossref funder ID: 100000090, ISNI: 0000 0000 9367 6288, Wikidata: Q45134126 | https://ror.org/03g2zjp07 | SCR_006456 | SciCrunch Registry | DOD CDMRP | 2026-10-31 12:14:37 | 53 | |||||
|
CHASM/SNV-Box Resource Report Resource Website 1+ mentions |
CHASM/SNV-Box (RRID:SCR_006445) | CHASM/SNV-Box | data or information resource, database, software resource | CHASM is a method that predicts the functional significance of somatic missense mutations observed in the genomes of cancer cells, allowing mutations to be prioritized in subsequent functional studies, based on the probability that they give the cells a selective survival advantage. SNV-Box is a database of pre-computed features of all possible amino acid substitutions at every position of the annotated human exome. Users can rapidly retrieve features for a given protein amino acid substitution for use in machine learning. | is listed by: OMICtools | Cancer | NCI CA152432; NCI CA135866; NSF DBI0845275 |
Acknowledgement requested, Free, Non-commercial | OMICS_00127 | SCR_006445 | SciCrunch Registry | CHASM / SNV-Box, Cancer-specific High-throughput Annotation of Somatic Mutations | 2026-10-31 12:14:23 | 3 | ||||||
|
DGIdb Resource Report Resource Website 100+ mentions |
DGIdb (RRID:SCR_006608) | DGIdb | application programming interface, data access protocol, data or information resource, database, software resource | A database of drug-gene relationships that provides drug-gene interactions and potential druggability data given list of genes. There are about 15 data sources that are being aggregated by DGIdb, with update date and these data sources are listed on this page: http://dgidb.genome.wustl.edu/sources, THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | drug, gene, interaction, bio.tools, FASEB list |
is listed by: OMICtools is listed by: bio.tools is listed by: Debian has parent organization: Washington University in St. Louis; Missouri; USA |
Cancer | NHGRI U54 HG003079 | PMID:24122041 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_155686, biotools:DGIdb, OMICS_01579 | https://bio.tools/DGIdb | SCR_006608 | SciCrunch Registry | Drug-Gene Interaction database, Drug Gene Interaction Database | 2026-10-31 12:14:33 | 408 | |||
|
UMD p53 Mutation Database Resource Report Resource Website 10+ mentions |
UMD p53 Mutation Database (RRID:SCR_006720) | p53 Database | data or information resource, data processing software, database, software application, software resource | The UMD TP53 Mutation Database is a novel web site exclusively dedicated to mutant TP53. The following datasets, analytical tools and software are available. * The TP53 UMD mutation database in human cancer (2012 release). This novel release (35,000 mutations, 3,600 publications) has been highly curated using an original and novel statistical procedure (See Edlung et al. PNAS 2012). * TP53MUTLOAD (MUTant Loss Of Activity Database), a novel database dedicated to detailed analysis of the properties of each TP53 mutant, ranging from transactivation to cell growth properties, change of conformation, localization or various gains of functions. The database contains more than 110,000 different entries. * TP53 Mut assessor, a novel stand-alone software available for both Windows and Mac users. Check your favorite TP53 mutants and get an instant identity card. Very useful to analyze any newly discovered TP53 mutants, as the software checks for every possible TP53 mutation. * MUT-TP53 2.0, an accurate and powerful tool that automatically manages p53 mutations and generate tables ready for publication, decreasing the risk of typing errors. MUT-TP53 2.0 also provides specific information for each TP53 mutation, allowing the user to assess the quality of the data. Up to 500 TP53 mutations can be managed simultaneously. | cell, dominant, germline, monoclonal, mutant, mutation, oncogene, p53, phylogenetic, polymorphism, prognosis, somatic, suppression, transform, tumor, tumorigenesis, umd, cell line | has parent organization: Karolinska Institute; Stockholm; Sweden | Cancer | Radiumhemmet Research Funds ; Cancerfureningen i Stockholm ; Swedish Cancer Society ; Swedish Research Council ; Swedish Cancer Foundation ; Jeansson Foundation ; Cancer Society in Stockholm ; Lions Cancer Research Fund Uppsala |
PMID:22628563 | Limited: The UMD p53 database is protected by the European Union Council Directive N����?�������� 96/9/EC, OJ (L77) 20 (1996). Extracting, Copying or reuse of data from databases without permission are covered by this directive. | nif-0000-21405 | http://p53.free.fr/Database/p53_database.html | SCR_006720 | SciCrunch Registry | UMD TP53 Mutation Database, UMD p53 Database, TP53 UMD mutation database | 2026-10-31 12:14:39 | 38 | |||
|
The Human Protein Atlas Resource Report Resource Website 5000+ mentions |
The Human Protein Atlas (RRID:SCR_006710) | HPA | data or information resource, knowledge base | Open access resource for human proteins. Used to search for specific genes or proteins or explore different resources, each focusing on particular aspect of the genome-wide analysis of the human proteins: Tissue, Brain, Single Cell, Subcellular, Cancer, Blood, Cell line, Structure and Interaction. Swedish-based program to map all human proteins in cells, tissues, and organs using integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics, and systems biology. All the data in the knowledge resource is open access to allow scientists both in academia and industry to freely access the data for exploration of the human proteome. | human proteins, human proteome exploration, genome-wide analysis of human proteins, Tissue, Brain, Single Cell, Subcellular, Cancer, Blood, Cell line, Structure and Interaction, bio.tools, FASEB list |
is used by: MitoMiner is listed by: re3data.org is listed by: bio.tools is listed by: Debian is related to: aGEM has parent organization: HUPO Antibody Initiative |
Cancer, Tumor, Breast cancer, Colorectal cancer, Lung cancer, Prostate cancer, Normal | Knut and Alice Wallenberg Foundation | PMID:21139605 PMID:16127175 PMID:18669619 PMID:18853439 |
Public, Free, For informational purposes, Non-commercial, Acknowledgement required | nif-0000-00204, biotools:proteinatlas | https://bio.tools/proteinatlas | SCR_006710 | SciCrunch Registry | HPA antibody, Human Protein Atlas | 2026-10-31 12:14:34 | 9312 | |||
|
VirusSeq Resource Report Resource Website 10+ mentions |
VirusSeq (RRID:SCR_005206) | VirusSeq | software resource | An algorithmic software tool for detecting known viruses and their integration sites using next-generation sequencing of human cancer tissue. VirusSeq takes FASTQ files (paired-end reads) as input. | next-generation sequencing, virus, integration site, cancer tissue, genome, rna-seq, whole genome sequencing, fastq, paired-end read, bio.tools |
is listed by: OMICtools is listed by: bio.tools is listed by: Debian has parent organization: University of Texas MD Anderson Cancer Center |
Cancer | OMICS_00227, biotools:virusseq | https://bio.tools/virusseq | SCR_005206 | SciCrunch Registry | 2026-10-31 12:14:10 | 23 | |||||||
|
SnpEff Resource Report Resource Website 5000+ mentions |
SnpEff (RRID:SCR_005191) | SnpEff | software resource | Genetic variant annotation and effect prediction software toolbox that annotates and predicts effects of variants on genes (such as amino acid changes). By using standards, such as VCF, SnpEff makes it easy to integrate with other programs. | genome, genetic variant, annotation, effect, variant, gene, cancer variant, gatk, hgsv, single nucleotide polymorphisms, genome sequence, java, bio.tools |
is listed by: OMICtools is listed by: Debian is listed by: bio.tools is related to: Galaxy is related to: GATK has parent organization: SourceForge has parent organization: Wayne State University; Michigan; USA works with: SnpSift |
Cancer | PMID:22728672 | Free, Freely available | biotools:snpeff, OMICS_00186 | https://bio.tools/snpeff, https://sources.debian.org/src/snpeff/ | SCR_005191 | SciCrunch Registry | SnpEff - Genetic variant annotation and effect prediction toolbox | 2026-10-31 12:14:08 | 5640 | ||||
|
SomaticSniper Resource Report Resource Website 100+ mentions |
SomaticSniper (RRID:SCR_005108) | SomaticSniper | software resource | Software program to identify single nucleotide positions that are different between tumor and normal (or, in theory, any two bam files). It takes a tumor bam and a normal bam and compares the two to determine the differences. It outputs a file in a format very similar to Samtools consensus format. It uses the genotype likelihood model of MAQ (as implemented in Samtools) and then calculates the probability that the tumor and normal genotypes are different. This probability is reported as a somatic score. The somatic score is the Phred-scaled probability (between 0 to 255) that the Tumor and Normal genotypes are not different where 0 means there is no probability that the genotypes are different and 255 means there is a probability of 1 ? 10(255/-10) that the genotypes are different between tumor and normal. This is consistent with how the SAM format reports such probabilities. It is currently available as source code via github or as a Debian APT package. |
is listed by: OMICtools has parent organization: Washington University in St. Louis; Missouri; USA |
Cancer, Tumor, Normal | PMID:22155872 | Acknowledgement requested | OMICS_00092 | SCR_005108 | SciCrunch Registry | 2026-10-31 12:14:04 | 152 | |||||||
|
SomaticIndelDetector Resource Report Resource Website 50+ mentions |
SomaticIndelDetector (RRID:SCR_005107) | SomaticIndelDetector | software resource | Tool for calling indels in Tumor-Normal paired sample mode. | cancer-specific variant discovery tool, variant, tumor, normal, bam, indel |
is listed by: OMICtools has parent organization: Broad Institute |
Cancer, Tumor, Normal | OMICS_00091 | SCR_005107 | SciCrunch Registry | 2026-10-31 12:14:09 | 82 | ||||||||
|
Oklahoma Medical Research Foundation Resource Report Resource Website 50+ mentions |
Oklahoma Medical Research Foundation (RRID:SCR_005287) | OMRF | institution | A biomedical research institute that aims to understand and develop more effective treatments for human disease, focusing on critical research areas such as heart disease, cancer, lupus and Alzheimer's disease. | human disease, cardiovascular disease, cancer, lupus, alzheimer’s disease, treatment, biomedical research institute |
is parent organization of: C. elegans Gene Knockout Consortium is parent organization of: Oklahoma Medical Research Foundation OMRF Clinical Genomics Center Core Facility |
Heart disease, Cancer, Lupus, Alzheimer's disease | Public | grid.274264.1, ISNI: 0000 0000 8527 6890, Wikidata: Q7082264, nlx_144327, Crossref funder ID: 100008907 | https://ror.org/035z6xf33 | SCR_005287 | SciCrunch Registry | 2026-10-31 12:14:11 | 61 | ||||||
|
University of Rochester Program for Brain Tumors and Spinal Tumors Resource Report Resource Website |
University of Rochester Program for Brain Tumors and Spinal Tumors (RRID:SCR_005343) | URMC Program for Brain and Spinal Tumors, | biomaterial supply resource, brain bank, material resource, tissue bank | Collaborative neuro-oncology research program with a tissue repository (tumor bank) containing a wide range of clinical specimens, which they make available to researchers in order to study the effects of new drugs on a large number and wide range of tumor specimens. They provide highly coordinated, complex care in neurosurgery, radiation oncology, medical oncology, and neurology to patients afflicted with tumors of the brain and spine by combining the newest technologies and treatments available anywhere in the world. The program is formed from a multidisciplinary group with a goal of helping patients navigate the complex issues surrounding brain and spinal cancer care. The researchers are working to increase the number of targets that could be considered for anti-angiogenesis therapy. Many of their studies focus on the blood vessel cells (endothelial cells) themselves, which, unlike tumor cells, rarely mutate and so might be less likely to become resistant to therapy and are also more easily reached through the bloodstream. Their researchers are also attempting to better understand the changes in the blood-brain barrier (BBB) that are associated with fluid accumulation and brain swelling (edema) in neuro-oncology patients. Normal brain tissue is shielded from the rest of the body by the BBB. This barrier is composed of very tight blood vessels that prevent most substances from entering the brain. Brain tumors have a leaky BBB ����?? this feature can be used to identify tumors on MRI scans. They have identified specific molecules that appear to be associated with the leaky, abnormal vessels while the normal blood vessels with intact BBB produce these molecules at very low levels or not at all. Inhibiting the function of these molecules may help control or prevent disruption of the BBB and limit cerebral edema in brain tumor patients, as well as patients suffering from stroke or traumatic brain injury. | brain tissue, brain, tissue, spine, spinal tumor, brain tumor, tumor, cancer, normal control, clinical trial, treatment, acoustic neuroma, anaplastic astrocytoma, brain metastases, brain stem glioma, chordoma, cns lymphoma, craniopharyngioma, ependymoma, gliomatosis cerebri, glioblastoma, low grade glioma, meningioma, medulloblastoma, oligodendroglioma, pineal tumor, pilocytic astrocytoma, pituitary adenoma, premature neuroectodermal tumor, oncology, neurooncology, stroke, traumatic brain injury, cerebral edema | is listed by: One Mind Biospecimen Bank Listing | Tumor, Brain tumor, Cancer, Spinal tumor, Normal control | Available to researchers - not clear if internally or if provide specimens to the public | nlx_144398 | http://www.urmc.rochester.edu/neurosurgery/neurooncology/overview/research/ | SCR_005343 | SciCrunch Registry | University of Rochester Brain Tumor and Spinal Tumor Program | 2026-10-31 12:14:03 | 0 | |||||
|
UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core Resource Report Resource Website |
UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core (RRID:SCR_005701) | UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core | analysis service resource, data analysis service, production service resource, service resource, training service resource | The Biostatistics Core provides statistical support for cancer-related research at UCSF, focusing particulary on applications in clinical trials and population studies. The Computational Biology Core supports applications to genomics, genetics and molecular biology. Core faculty have expertise in study design, protocol and proposal development and review, data analysis, and publication of results. Support for Cancer Center investigators participating in established Site Committees is typically handled by the faculty member assigned to that committee. Other requests can be directed to the consulting service request page maintained by the UCSF Clinical & Translational Science Institute (CTSI). These requests will then be assigned to a Core faculty member. Basic consulting services are generally provided free of charge to Cancer Center Members. Members requiring frequent assistance are encouraged to provide regular salary support to a Core statistician when possible to support more extensive requests and for long-term projects. Services: * Study Design * Guidance on Study Conduct * Data Analysis and Reporting of Study Results * Teaching resources |
has parent organization: UCSF Helen Diller Family Comprehensive Cancer Center is parent organization of: EGAN: Exploratory Gene Association Networks |
Cancer | nlx_149150 | http://cancer.ucsf.edu/cores/biostatistics/index.php | SCR_005701 | SciCrunch Registry | UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics and Computational Biology Core | 2026-10-31 12:14:15 | 0 | |||||||
|
Terry Fox Foundation Resource Report Resource Website 1+ mentions |
Terry Fox Foundation (RRID:SCR_005873) | TFF | institution | The Terry Fox Foundation is responsible for supporting close to $20 million in discovery based research each year in Canada - all monies raised outside Canada must be distributed to (a) an institute approved by the Foundation and its advisors or (b) remitted to Canada. The Terry Fox Research Institute (TFRI) is a recipient of TFF funding for translational research. TFRI is an exciting new initiative whose goal is to translate rapidly today''s best science into better cancer treatment and diagnosis for all Canadians. The Institute will bring scientists and clinicians together across the country into a functionally integrated, geographically dispersed Institute with nodes in several provinces. Terry Fox was diagnosed with osteogenic sarcoma (bone cancer) in his right leg in 1977 and had his leg amputated 15 cm (six inches) above the knee. While in hospital, Terry was so overcome by the suffering of other cancer patients that he decided to run across Canada to raise money for cancer research. He called his journey the Marathon of Hope. Terry''s Marathon of Hope took place in 1980 with the simple objective of informing Canadians of the importance of finding a cure for cancer. With fierce determination, he ran an average of 42 kilometres (26 miles) every day for 143 days. Terry was forced to end his run on September 1, 1980 when the cancer spread to his lungs. By February 1, 1981, Terry''s dream of raising $1 for every Canadian was realized - the Terry Fox Marathon of Hope fund totaled $24.17 million. Terry died in June 1981. On May 26, 1988, The Terry Fox Run became a Trust, independent from the Canadian Cancer Society, and received tax-exempt charitable registration as a public foundation. In addition to our signature and long-standing National Terry Fox Run Day in September of each year, The Terry Fox Foundation is proud to include in its events portfolio The National School Run Day. The Foundation recognizes the duality of its mandate. Not only does it raise money for research, but it also continues to share the story of Terry Fox. The Terry Fox Foundation strives to maintain the heroic effort and integrity that Terry embodied. It is a grassroots organization that does not allow the Terry Fox name or likeness to be commercialized or conjoined with other worthy causes. To date, over $600 million has been raised worldwide for cancer research in Terry''s name. | research, cancer | is parent organization of: Terry Fox Research Institute | Cancer | ISNI: 0000 0004 5907 4557, Crossref funder ID: 501100002655, nlx_149429, grid.453650.1 | https://ror.org/05vd00053 | SCR_005873 | SciCrunch Registry | 2026-10-31 12:14:17 | 5 | |||||||
|
Research Accelerator Resource Report Resource Website 1+ mentions |
Research Accelerator (RRID:SCR_006051) | UCSD Research Accelerator | community building portal, data or information resource, database, portal, service resource | Software platform that allows researchers to easily collaborate on research and share reagents, antibodies, cell lines and more. It is designed to increase scientific collaboration across disciplines and geographical boundaries. Among the institutions now using the platform include Yale University, U of Pennsylvania, U of Chicago, Washington U, Cambridge University, University College London. The platform is licensed to select institutions. ResearchAccelerator.org allows researchers to form targeted, data driven collaborations. Researchers can search for data based on gene, disease and pathway, and they can post data which would otherwise be orphaned. The resulting collaborations, which are likely to be transdisciplinary, can greatly amplify impact and research productivity. | collaboration, transdisciplinary research, gene, pathway, disease, cell line, data, human sample, laboratory protocol, medical device, equipment, resource, reagent, research project, transgenic animal, knock out animal, validated antibody, yale keck proteomics assay, allergy, immunology, bone, joint, orthopedic, cancer, cardiovascular, gastroenterology, infectious disease, neurologic disease, organ transplantation, psychiatric disease, reproductive disease, vascular disease, sharing, material resource |
is used by: University College London; London; United Kingdom is used by: University of Cambridge; Cambridge; United Kingdom is used by: Washington University in St. Louis; Missouri; USA is used by: University of Chicago; Illinois; USA is used by: University of Pennsylvania; Philadelphia; USA is used by: Yale University; Connecticut; USA has parent organization: University of California at San Diego; California; USA |
Allergy, Immunology, Bone, Joint, Orthopedic, Cancer, Cardiovascular, Gastroenterology, Infectious Disease, Neurologic disease, Organ Transplantation, Psychiatric disease, Reproductive disease, Vascular disease | The community can contribute to this resource | nlx_151451 | SCR_006051 | SciCrunch Registry | ResearchAccelerator.org, ResearchAccelerator | 2026-10-31 12:14:28 | 1 | ||||||
|
ACTREC - Advanced Centre for Treatment Research and Education in Cancer Resource Report Resource Website 1+ mentions |
ACTREC - Advanced Centre for Treatment Research and Education in Cancer (RRID:SCR_006021) | ACTREC | institution | The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer. TMC is an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India. It is registered under the Societies Registration Act (1860) and the Bombay Public Trust Act (1950). Its Governing Council is headed by the Chairman, Atomic Energy Commission, Government of India. ACTREC comprises of 2 arms - one for basic research and another for clinical research. The basic research building was inaugurated in March 2002 at the new site of ACTREC in Kharghar, Navi Mumbai. In August 2002, the Cancer Research Institute (CRI) shifted in toto from its Parel campus in Mumbai to serve as the basic research arm of ACTREC. The clinical research arm of ACTREC comprising of the Clinical Research Centre (CRC) has become functional from March 2005. ACTREC also has a 50-bed hospital fully equipped with state-of-the-art diagnostic and therapeutic facilities. Research investigations at CRI currently focus on molecular mechanisms responsible for causation of major human cancers relevant to India. It is envisaged that in the future, ACTREC will play a greater role in drug development and emerging therapies for treatment and prevention of cancer. | cancer, basic research, clinical research, drug development, therapy, treatment, prevention, research, education | is parent organization of: HIstome: The Histone Infobase | Cancer | Crossref funder ID: 501100007179, ISNI: 0000 0004 1766 7522, grid.410869.2, nlx_151418 | https://ror.org/05b9pgt88 | SCR_006021 | SciCrunch Registry | Advanced Centre for Treatment Research and Education in Cancer | 2026-10-31 12:14:28 | 2 | ||||||
|
Hybrigenics Resource Report Resource Website 10+ mentions |
Hybrigenics (RRID:SCR_003822) | commercial organization | A bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Its current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications: * alone in chronic lymphocytic leukaemia * in combination with imatinib in chronic myeloid leukaemia * in prostate cancer, for use with current standards of care Hybrigenics'' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells. | enzyme, proteomic, protein interaction network, protein interaction | is related to: AgedBrainSYSBIO | Lymphocytic leukaemia, Myeloid leukaemia, Prostate cancer, Cancer | nlx_158127 | SCR_003822 | SciCrunch Registry | 2026-10-31 12:13:33 | 16 | |||||||||
|
Amorfix Resource Report Resource Website 1+ mentions |
Amorfix (RRID:SCR_003783) | AMF | commercial organization | Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc. | diagnostic, therapy, alzheimer, protein, misfolded protein disease | Alzheimer's disease, Amyotrophic Lateral Sclerosis, Cancer | Crossref funder ID: 100007611, nlx_158072, grid.422608.a | https://ror.org/045rtab03 | SCR_003783 | SciCrunch Registry | Amorfix Life Science, Amorfix Life Sciences Ltd., Amorfix Life Sciences, ProMIS Neurosciences | 2026-10-31 12:13:33 | 2 | |||||||
|
ChemoCentryx Resource Report Resource Website 10+ mentions |
ChemoCentryx (RRID:SCR_003976) | commercial organization | A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biopharmaceutical, oral administration, medicine, small molecule, chemokine, chemo-attractant receptor, clinical, drug, oral drug | is related to: Kidney Health Initiative | Autoimmune disease, Inflammatory disorder, Cancer | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158383, grid.452218.8, ISNI: 0000 0004 0408 7502 | https://ror.org/04gp12571 | SCR_003976 | SciCrunch Registry | ChemoCentryx Inc, ChemoCentryx Inc. | 2026-10-31 12:13:39 | 43 | ||||||
|
C. R. Bard Resource Report Resource Website 1+ mentions |
C. R. Bard (RRID:SCR_003975) | BARD, BCR | commercial organization | A multinational developer, manufacturer, and marketer of medical technologies specializing in the manufacture of vascular, urology, oncology and surgical specialty products. BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs. Bard is perhaps best known for having introduced the Foley catheter. (Adapted from Wikipedia) | medical equipment, vascular, urology, oncology, surgical, medical technology, medical, clinical | is related to: Kidney Health Initiative | Cancer | nlx_158382 | SCR_003975 | SciCrunch Registry | C. R. Bard Inc., C.R. Bard Inc., C. R. Bard Inc, CR Bard, C.R. Bard Inc, C.R. Bard, CR Bard Inc. | 2026-10-31 12:13:35 | 2 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant U24DK097771.
Email: info_at_ dknet.org
